Follow
Bart Neyns
Bart Neyns
Diensthoofd, Medische Oncologie, Universitair Ziekenhuis Brussel
Verified email at uzbrussel.be
Title
Cited by
Cited by
Year
Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
New England Journal of Medicine 372 (26), 2521-2532, 2015
57742015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ...
The lancet oncology 16 (4), 375-384, 2015
29372015
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ...
Journal of clinical oncology 25 (13), 1658-1664, 2007
24052007
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ...
Journal of clinical oncology 36 (8), 773-779, 2018
18662018
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
JD Wolchok, B Neyns, G Linette, S Negrier, J Lutzky, L Thomas, ...
The lancet oncology 11 (2), 155-164, 2010
14092010
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J Schachter, A Ribas, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet 390 (10105), 1853-1862, 2017
12602017
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ...
The Lancet Oncology 20 (9), 1239-1251, 2019
9922019
KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma
C Robert, J Schachter, GV Long, A Arance, JJ Grob, L Mortier, A Daud, ...
N Engl J Med 372 (26), 2521-2532, 2015
5912015
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma
TT Batchelor, P Mulholland, B Neyns, LB Nabors, M Campone, A Wick, ...
Journal of Clinical Oncology 31 (26), 3212, 2013
5842013
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ...
Journal of Clinical Oncology 35 (2), 226, 2017
5382017
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed …
R Stupp, ME Hegi, B Neyns, R Goldbrunner, U Schlegel, PM Clement, ...
Journal of clinical oncology 28 (16), 2712-2718, 2010
5182010
Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label …
J Larkin, D Minor, S D'Angelo, B Neyns, M Smylie, WH Miller Jr, ...
Journal of clinical oncology 36 (4), 383, 2018
5092018
First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
HJ Lenz, E Van Cutsem, M Luisa Limon, KYM Wong, A Hendlisz, ...
Journal of Clinical Oncology 40 (2), 161-170, 2022
3402022
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
J Larkin, M Del Vecchio, PA Ascierto, I Krajsova, J Schachter, B Neyns, ...
The Lancet Oncology 15 (4), 436-444, 2014
3162014
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization
AR Pombo Antunes, I Scheyltjens, F Lodi, J Messiaen, A Antoranz, ...
Nature neuroscience 24 (4), 595-610, 2021
3062021
Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma
S Wilgenhof, J Corthals, C Heirman, N van Baren, S Lucas, P Kvistborg, ...
J clin oncol 34 (12), 1330-8, 2016
2972016
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B Neyns, J Sadones, E Joosens, F Bouttens, L Verbeke, JF Baurain, ...
Annals of Oncology 20 (9), 1596-1603, 2009
2832009
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients
A Bonehill, AMT Van Nuffel, J Corthals, S Tuyaerts, C Heirman, ...
Clinical Cancer Research 15 (10), 3366-3375, 2009
2702009
Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab
J de Filette, Y Jansen, M Schreuer, H Everaert, B Velkeniers, B Neyns, ...
The Journal of Clinical Endocrinology & Metabolism 101 (11), 4431-4439, 2016
2292016
Current approaches in dendritic cell generation and future implications for cancer immunotherapy
S Tuyaerts, JL Aerts, J Corthals, B Neyns, C Heirman, K Breckpot, ...
Cancer Immunology, Immunotherapy 56, 1513-1537, 2007
2252007
The system can't perform the operation now. Try again later.
Articles 1–20